Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Universal Detection Technology responds to the U.S. Government's failure to address bioterrorism

Universal Detection Technology responds to the U.S. Government's failure to address bioterrorism

NewsRx publishes new encyclopedia on vaccines

NewsRx publishes new encyclopedia on vaccines

UCF researcher develops first dual vaccine to fight malaria and cholera

UCF researcher develops first dual vaccine to fight malaria and cholera

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

EPO grants notice of allowance for Response Biomedical’s ‘Fong Patent’

EPO grants notice of allowance for Response Biomedical’s ‘Fong Patent’

Special Notice announces BARDA's intentions to negotiate contract modification with PharmAthene

Special Notice announces BARDA's intentions to negotiate contract modification with PharmAthene

Medizone International completes third round of testing and data logging for AsepticSure technology

Medizone International completes third round of testing and data logging for AsepticSure technology

Elusys Therapeutics signs contract to complete the final development of Anthim

Elusys Therapeutics signs contract to complete the final development of Anthim

Promising results from Soligenix' RiVax vaccine against ricin toxin

Promising results from Soligenix' RiVax vaccine against ricin toxin

Elusys Therapeutics receives contract to speed up drug development for Anthrax

Elusys Therapeutics receives contract to speed up drug development for Anthrax

Former CDC head to lead Merck's vaccine division

Former CDC head to lead Merck's vaccine division

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

STERIPLEX HC kills MRSA and other pathogens in record time

STERIPLEX HC kills MRSA and other pathogens in record time

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

Plans moving forward for Medizone International's hospital sterilization system, AsepticSure

Plans moving forward for Medizone International's hospital sterilization system, AsepticSure

Advanced Life Sciences Holdings' Restanza promising against tularemia

Advanced Life Sciences Holdings' Restanza promising against tularemia

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

Novartis submits JOULFERON MAA to the EMEA

Novartis submits JOULFERON MAA to the EMEA

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

Human Genome Sciences closes public offering of new issued shares

Human Genome Sciences closes public offering of new issued shares

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.